Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Huperzine A

Phase 3Small molecule

WWanbangde Pharmaceutical Group Co., LTD

Huperzine A is one of 70 small molecule programs targeting Delirium. It is currently in Phase 3.

3

Indications

12

Total Trials

3

Active Trials

69

Competitors

Pipeline

Status by Indication[3][1]

Indication

DeliriumActive, not recruiting

OralUnknown status

Cognitive Impairment After Brain InjuryRecruiting

DeliriumPreclinical

Active, not recruiting

OralPreclinical

Unknown status

Cognitive Impairment After Brain InjuryPhase 3

Recruiting

Competition

Competitive Landscape

78 competitors in Delirium

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Exelon

Rozerem

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Voltaren

Aleve

Jazz Pharmaceuticals

Duragesic

Anerem

AAcacia Pharma Ltd

Spravato

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

ApprovedRecruiting

Cognitive Impairment After Brain Injury

NCT06704334

Q3 2028

PreclinicalRecruiting

Alzheimer Dementia

NCT07066826

Clinical

Trials by Indication[1]

Alzheimer's Disease3 trials

Huperzine A in Alzheimer's Disease

Completed·NNational Institute on Aging (NIA)·Phase 2·NCT00083590·150 enrolled

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Unknown status·SShandong Luye Pharmaceutical Co., Ltd.·Phase 2/3·NCT01282619·390 enrolled

Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

Unknown status·SShanghai Mental Health Center·Phase 4·NCT02931136·300 enrolled

Central Nervous System1 trial

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

Completed·UU.S. Army Medical Research and Development Command··NCT01194336·84 enrolled

Delirium1 trial

A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery

Recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·N/A·NCT05242419·40 enrolled

Cocaine Dependence1 trial

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence

Completed·—·Phase 1·NCT01030692·72 enrolled

Schizophrenia1 trial

Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia

Unknown status·VVA Nebraska Western Iowa Health Care System·Phase 4·NCT01012830·15 enrolled

5 more indications

Treatment1 trial

Effects of Huperzine A in Treatment of Moderate to Severe TBI

Terminated·SSpaulding Rehabilitation Hospital·Phase 2·NCT01676311·14 enrolled

Oral1 trial

Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A

Unknown status·HHadassah Medical Organization·N/A·NCT01136551·8 enrolled

Alzheimer Dementia1 trial

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel-Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Recruiting·WWanbangde Pharmaceutical Group Co., LTD·Preclinical·NCT07066826·720 enrolled

Cognitive Impairment After Brain Injury1 trial

The Study of Ginkgo Leaf Dropping Pills and Huperzine A Injection Combined With Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury

Recruiting·WWanbangde Pharmaceutical Group Co., LTD·Approved·NCT06704334·50 enrolled

Unspecified1 trial

The Study of Pharmacokinetics and Pharmacodynamics of Huperzine A Injection in Healthy Chinese Subjects

Completed·WWanbangde Pharmaceutical Group Co., LTD·Phase 1·NCT06570655·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Huperzine A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Huperzine A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Huperzine A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wanbangde Pharmaceutical Group Co., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWanbangde Pharmaceutical Group Co., LTD

Related News